Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dapagliflozin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Dapagliflozin. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2019-002262-12 Sponsor Protocol Number: DAPA-OB Start Date*: 2021-05-17
    Sponsor Name:Hospital Universitari Germans Trias i Pujol
    Full Title: "Effect of dapagliflozin on glomerular hyperfiltration in nondiabetic obese patients with or without treatment with ACEIs". Pilot clinical trial of efficacy, low level of intervention, unicentric, ...
    Medical condition: This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glom...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005406-11 Sponsor Protocol Number: D1683C00005 Start Date*: 2016-05-25
    Sponsor Name:Astrazeneca AB
    Full Title: A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered with Dapagliflozin 5mg compared t...
    Medical condition: Type 2 diabetes mellitus, inadequate glycaemic control
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-001441-24 Sponsor Protocol Number: CUI_001 Start Date*: 2014-08-08
    Sponsor Name:Medical University Innsbruck
    Full Title: Short-term effect of SGLT 2-inhibitor dapagliflozin on postprandial glucose excursion and insulin sensitivity in type 1 diabetic patients.
    Medical condition: effects of Dapagliflozin on postprandial glucose excursion and fasting glucose homeostasis
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000715-33 Sponsor Protocol Number: 2015DM07 Start Date*: 2016-12-19
    Sponsor Name:University of Dundee & NHS Tayside
    Full Title: Does Dapaglifozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
    Medical condition: Type 2 diabetes and left ventricular hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10061024 Cardiac disorder PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001473-79 Sponsor Protocol Number: ESR-20-20653 Start Date*: 2020-05-07
    Sponsor Name:Saint Luke’s Hospital of Kansas City, Kansas City, Missouri, USA
    Full Title: An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19
    Medical condition: Respiratory Failure in patients with COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-002742-42 Sponsor Protocol Number: 2013DM19 Start Date*: 2014-12-23
    Sponsor Name:University of Dundee/ NHS Tayside
    Full Title: Research into the Effect Of SGLT2 inhibition on left ventricular Remodelling in patients with heart failure and diabetes Mellitus
    Medical condition: Type 2 diabetes and Heart Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002376-24 Sponsor Protocol Number: D1689C00014 Start Date*: 2015-10-06
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin plus Saxagliptin compared ...
    Medical condition: Type 2 diabetes mellitus, inadequate glycaemic control
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003897-41 Sponsor Protocol Number: D1699C00001 Start Date*: 2017-01-19
    Sponsor Name:AstraZeneca AB
    Full Title: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction
    Medical condition: Chronic Heart Failure (HF) with Reduced Ejection Fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) DE (Completed) DK (Completed) BG (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002676-24 Sponsor Protocol Number: D1690C00023 Start Date*: 2015-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: An exploratory Phase II/III, randomized, double-blind, placebo controlled, parallel design study to evaluate the efficacy, safety and pharmacodynamics of dapagliflozin and dapagliflozin in combinat...
    Medical condition: CKD3 patients with type 2 diabetes mellitus and albuminuria.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-003896-24 Sponsor Protocol Number: D169AC00001 Start Date*: 2017-01-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
    Medical condition: Chronic kidney disease (CKD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Completed) DE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001237-27 Sponsor Protocol Number: ESR-14-10158 Start Date*: 2016-09-01
    Sponsor Name:Instituto Gallego de Medicina Vascular (IGAMEVAS S.L.)
    Full Title: A randomized, unicenter, parallel study of the effect of dapagliflozin on central blood pressure reduction compared to glimepiride in adult subjects with type 2 Diabetes Mellitus and inadequate gly...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003991-27 Sponsor Protocol Number: D1690C00047 Start Date*: 2017-12-27
    Sponsor Name:AstraZeneca AB
    Full Title: MAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Sk...
    Medical condition: Study to investigate mitochondrial function and insulin sensitivity in skeletal muscle in subjects with T2DM.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003638-26 Sponsor Protocol Number: D5883C00004 Start Date*: 2014-12-03
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind randomized placebo-controlled, parallel-group 12 week study to investigate the effects of Epanova® and dapagliFlozin on liver Fat contEnt in type 2 diabetiC patienTs;
    Medical condition: Patients with type 2-diabetes who have Non-alcoholic fatty liver disease (NAFLD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005377-36 Sponsor Protocol Number: D1690C00025 Start Date*: 2015-02-26
    Sponsor Name:AstraZeneca AB, R&D Mölndal
    Full Title: An 8-week, single centre, randomized, parallel-group, double-blind, placebo controlled phase IV study to evaluate Dapagliflozin 10 mg once daily effects on insulin resistance in subjects with type ...
    Medical condition: type 2 diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-000804-24 Sponsor Protocol Number: D1690C00024 Start Date*: 2015-07-06
    Sponsor Name: AstraZeneca AB
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III study to Evaluate the Glycemic Efficacy and Renal Safety of dapagliflozin in patients with Type 2 Diabetes Mel...
    Medical condition: Type 2 Diabetes Mellitus with Moderate Renal Impairment (CKD 3A)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005225-40 Sponsor Protocol Number: MB102-091 Start Date*: 2013-05-27
    Sponsor Name:Bristol-Myers Squibb Company
    Full Title: A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years with Type 2 Diabetes Mellitus
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000664-31 Sponsor Protocol Number: D169DC00001 Start Date*: 2020-08-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Ac...
    Medical condition: Acute Myocardial Infarction, Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-004709-42 Sponsor Protocol Number: NL63792.099.17 Start Date*: 2018-04-24
    Sponsor Name:Martini Hospital
    Full Title: An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004878-17 Sponsor Protocol Number: 0.1 Start Date*: 2017-07-20
    Sponsor Name:University of Leicester
    Full Title: The Effect of a SGLT2 inhibitor on Glucose flux, Lipolysis and Exercise in type 2 Diabetes
    Medical condition: Type 2 diabetes.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:19:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA